249,812 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Tudor Investment Corp ET AL
by Teresa Graham · The Cerbat GemTudor Investment Corp ET AL acquired a new position in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 249,812 shares of the company’s stock, valued at approximately $867,000.
Other institutional investors have also recently bought and sold shares of the company. Federated Hermes Inc. raised its position in Cytek Biosciences by 150.9% in the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock worth $25,000 after purchasing an additional 4,343 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in Cytek Biosciences in the 3rd quarter worth approximately $43,000. Captrust Financial Advisors bought a new position in Cytek Biosciences in the 2nd quarter worth approximately $43,000. Tower Research Capital LLC TRC raised its position in shares of Cytek Biosciences by 338.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company’s stock valued at $67,000 after acquiring an additional 15,250 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Cytek Biosciences during the 3rd quarter valued at $75,000. Institutional investors own 69.46% of the company’s stock.
Cytek Biosciences Trading Up 0.7%
Shares of CTKB opened at $4.62 on Wednesday. The firm’s 50 day moving average is $4.41 and its 200-day moving average is $4.67. The stock has a market capitalization of $590.71 million, a PE ratio of -9.06 and a beta of 1.28. Cytek Biosciences, Inc. has a 12 month low of $2.37 and a 12 month high of $6.18.
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.36). The company had revenue of $62.14 million for the quarter, compared to the consensus estimate of $58.80 million. Cytek Biosciences had a negative return on equity of 7.70% and a negative net margin of 33.02%. Equities research analysts predict that Cytek Biosciences, Inc. will post -0.06 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CTKB has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytek Biosciences in a report on Friday, March 27th. TD Cowen restated a “buy” rating on shares of Cytek Biosciences in a research note on Thursday, January 8th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.38.
Get Our Latest Stock Analysis on CTKB
Cytek Biosciences Company Profile
Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.
The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.
Featured Articles
Want to see what other hedge funds are holding CTKB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report).